Bharat Electronics Limited (BEL), a Navratna Defence Public Sector Undertaking, has announced securing additional orders worth ₹561 crores since its last disclosure on December 23, 2024.

These new orders include communication equipment, electro-optics, upgrades for SATCOM networks, radar and fire control systems, spares, and services.

With these orders, BEL’s total order intake for the current financial year has reached ₹10,362 crores, reinforcing its position as a key player in India’s defence manufacturing ecosystem.

Financial Performance Highlights: Q2 FY25 and H1 FY25

BEL demonstrated growth in Q2 FY25, with revenue from operations rising to ₹4,58,341 lakh compared to ₹3,99,332 lakh in Q2 FY24. Profit after tax for the quarter surged to ₹1,09,127 lakh, from ₹81,234 lakh in Q2 FY24.

For H1 FY25, revenue from operations stood at ₹8,78,218 lakh, reflecting a growth from ₹7,50,416 lakh in H1 FY24. Net profit for H1 FY25 was ₹1,86,741 lakh, marking an increase from ₹1,34,318 lakh in H1 FY24.

About Bharat Electronics Limited

Bharat Electronics Ltd was incorporated in 1954. The company is involved in the manufacturing and supplying of electronic equipment and systems to the defence sector. The company also has a limited presence in the civilian market.

On January 14, 2025, BEL share price opened at ₹263.00, touching the day’s high at ₹265.95, as of 9:46 AM on the NSE.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Puravankara Limited recorded notable financial and operational achievements for Q3 FY25 and the nine months ended December 31, 2024 (9MFY25).

The company reported sales of ₹1,265 crores for Q3 FY25, a 2% increase compared to ₹1,241 crores in Q3 FY24. For 9MFY25, sales value reached ₹3,724 crores, demonstrating strong momentum.

Customer Collections and Pricing Trends

Customer collections showed growth, increasing by 6% year-on-year (YoY) to ₹993 crores in Q3 FY25 compared to ₹941 crores in the same quarter of the previous year. For the nine-month period, customer collections surged 19%, reaching ₹2,991 crores compared to ₹2,515 crores in 9MFY24. Additionally, the average price realisation for Q3 FY25 increased significantly to ₹8,848 per square foot (sft), a 16% rise compared to ₹7,621 per sft in Q3 FY24.

Strategic Investments in Land Acquisition

Puravankara spent over ₹1,100 crores on land acquisitions during the fiscal year, securing a potential gross development value (GDV) of ₹10,500 crores. These investments align with the company’s long-term growth strategy and strengthen its position in the consolidating real estate market.

Market Outlook

The company stated that the real estate sector in India continues to witness strong foreign equity investments, which reached an all-time high of $11.4 billion in 2024. The absorption of over 70 million square feet of office space across six major cities during the year highlights robust commercial demand driven by Global Capability Centers (GCCs) and hiring growth.

While delays in approvals affected new launches in 9MFY25, Puravankara plans to expedite its pipeline with 15.70 million sq. ft of projects scheduled for launch between Q4 FY25 and Q1 FY26. The company remains optimistic about increasing its market share amid favourable economic fundamentals and anticipated policy measures in the upcoming Union Budget to boost infrastructure, private investments, and foreign direct investments (FDI).

Commenting on the performance, the Managing Director of Puravankara Ltd, Ashish Puravankara, said, “The growth in collections is a clear reflection of our strong operational efficiency. In 9MFY25, we achieved collections of Rs. 2,991 crore, a 19% Y-o-Y increase, with Rs. 993 crore in Q3FY25, a 6% increase Y-o-Y. Pre-sales for Q3FY25 reached Rs. 1,265 crore, up by 2% Y-o-Y. Keeping in line with our acquisition strategy and our growth plans for the current and next financial year, we have invested approximately Rs. 1,100 crores this fiscal, adding a potential GDV of around Rs. 10,500 crores. This includes our most recent acquisition in Kanakapura Road, Bengaluru.”

On January 14, 2025, Puravankara share price opened at ₹335.00, touching the day’s low at ₹325.75, as of 9:47 AM on the NSE.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

HCL Technologies Limited (HCLTech) reported its financial performance for the quarter ended December 31, 2024.

On January 13, 2025, HCLTech share price closed at ₹1,975.00, down by 1.01%. Notably, the stock price touched its 52-week high on January 13, 2025, at ₹2,012.20 on the NSE.

Q3 FY 2025 Financial Highlights

The company’s revenue stood at ₹29,890 crore, marking a 3.6% quarter-on-quarter (QoQ) growth and a 5.1% year-on-year (YoY) rise. The Earnings Before Interest and Tax (EBIT) reached ₹5,821 crore, representing 19.5% of revenue, with an 8.6% QoQ and 3.7% YoY increase. Net Income (NI) also demonstrated growth, reaching ₹4,591 crore, accounting for 15.4% of revenue, up 8.4% QoQ and 5.5% YoY.

Interim Dividend Declaration

To commemorate 25 years of its public listing, HCLTech’s Board of Directors declared a fourth interim dividend of ₹18 per equity share (₹2 face value). This includes a special dividend of ₹6 per share. The record date for this dividend is January 17, 2025, and the payment will be made on January 24, 2025.

FY25 Guidance

For FY25, HCLTech expects revenue growth of 4.5%–5.0% YoY in constant currency (CC). The company also projects services revenue growth to align with the same range. The EBIT margin guidance has been set at 18.0%–19.0%.

Expansion of Strategic Partnership with Microsoft

In another filing, HCLTech announced the expansion of its collaboration with Microsoft to revolutionise customer service experiences using generative AI and cloud-based solutions. The partnership focuses on Microsoft Dynamics 365 Contact Center, a Copilot-first solution that leverages advanced AI capabilities to enhance customer interactions, accelerate issue resolution, and boost efficiency. This move positions HCLTech as a frontrunner in offering cutting-edge solutions for customer service transformation.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Mangalore Refinery and Petrochemicals Limited (MRPL) has announced the launch of its Toluene production facility during a visit by the Hon’ble Minister of Petroleum and Natural Gas, Shri Hardeep Singh Puri, to its refinery. This milestone aligns with India’s vision of self-reliance and global competitiveness in the petrochemical sector.

Significant Contribution to Domestic Toluene Production

With an annual production capacity of 40 TMT, MRPL’s Toluene facility marks a substantial step toward reducing India’s dependency on imports. Currently, the domestic production of Toluene stands at 160 TMT against a demand of approximately 650 TMT per year. MRPL’s addition will help address this gap while saving $3 million annually in foreign exchange.

Toluene, a versatile aromatic hydrocarbon, is essential for industries such as pharmaceuticals, chemicals, paints, and defence. By enhancing domestic production, MRPL strengthens India’s industrial supply chain, enabling growth in key sectors.

The initiative is a testament to India’s progress toward becoming self-reliant in critical resources. MRPL’s efforts will not only boost the economy but also reduce dependency on imports, supporting industrial and economic growth in line with the Atmanirbhar Bharat mission.

On January 13, 2025, MRPL share price opened at ₹139.00, touching the day’s high at ₹144.44, as of 9:47 AM on the NSE.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Wockhardt Limited informed the exchanges that in a groundbreaking clinical study, Zaynich® demonstrated exceptional efficacy, with over 97% clinical success in treating patients with infections caused by carbapenem-resistant Gram-negative pathogens, including meropenem-resistant strains.

Zaynich® is Wockhardt’s novel proprietary antibiotic that combines Zidebactam and Cefepime (WCK 5222).

The study addressed severe infections such as hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), bloodstream infections (BSI), complicated intra-abdominal infections (cIAI), and complicated urinary tract infections (cUTI). For bloodstream infections, HABP/VABP, and cIAI, Zaynich® achieved a remarkable 100% clinical efficacy.

High Efficacy and Pathogen Eradication Rates

Zaynich® also achieved notable pathogen eradication rates, including 91% for HABP/VABP and 100% for bloodstream infections. The study included critically ill patients across 15 tertiary care hospitals in India, focusing exclusively on carbapenem-resistant Gram-negative infections caused by pathogens like Acinetobacter spp., Pseudomonas spp., Klebsiella spp., and E. coli.

Using advanced molecular diagnostic technologies, the study highlighted Zaynich®’s effectiveness even against extensively drug-resistant (XDR) infections. Treatment durations ranged from 7 to 21 days, with the protocol receiving approval from the Drugs Controller General of India (DCGI).

Addressing the Global Threat of Antimicrobial Resistance

Zaynich® emerges as a game-changer in the fight against antimicrobial resistance (AMR), a growing global threat. Unlike current options such as colistin and polymyxins, which have significant toxicity and limited efficacy, Zaynich® provides a safer and more effective alternative.

It targets critical Gram-negative pathogens identified by the CDC and WHO, making it a valuable tool in combating life-threatening infections. With over 100 critically ill patients saved through its compassionate use in India and the US, Zaynich® sets a new benchmark for treating drug-resistant infections, offering hope for improved patient outcomes worldwide.

On January 13, 2025, Wockhardt share price (NSE: WOCKPHARMA) opened at ₹1,380.00, touching the day’s high at ₹1,442.00, as of 9:58 AM on the NSE.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

On January 13, 2025, as of 12 PM, the BSE Sensex was down 619.83 points (-0.80%) at 76,759.08, while the Nifty50 was down by 205.05 points (-0.88%) at 23,225.90. Among sectors, only the Nifty Realty dropped 4.29%.

As of January 13, 2025, 12:03 IST, the mid-day top gainers and losers are:

Mid-Day Top Gainers 

• Axis Bank

Axis Bank share price rose 1.43%, opening at ₹1,026.60 and touching the day’s high at ₹1,063.00.

• IndusInd Bank

IndusInd Bank share price gained 1.34%, opening at ₹936.90 and touching the day’s high at ₹973.50.

• TCS

Tata Consultancy Services share price surged 0.95%, opening at ₹4,245.00, hitting a high of ₹4,316.80.

• Shriram Finance

Shriram Finance share price surged 0.49%, opening at ₹530.05, hitting a day’s high of ₹540.70.

• Infosys 

Infosys Share Price rose by 0.11%, opening at ₹1,956.00, hitting a day’s high of ₹1,982.80.

Mid-Day Top Losers

• Trent

Trent share price dropped 5.11%, opening at ₹6,462.65. The stock touched its day’s low at ₹6,228.55.

• Adani Enterprises 

Adani Enterprises Share Price fell 3.11%, opening at ₹2,365.00. The stock touched its day’s low at ₹2,295.00.

• Apollo Hospitals Enterprise

Apollo Hospitals share price dropped 2.99%, opening at ₹7,000.00. The stock touched its day’s low at ₹6,812.05.

• Grasim Industries

Grasim Industries share price slipped 2.33%, opening at ₹2,329.95. The stock touched its day’s low at ₹2,302.00.

• Eicher Motors

Eicher Motors share price slipped 2.39%, opening at ₹5,010.00. The stock touched its day’s low at ₹4,930.00.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

CESC Ltd has been in focus on Monday. On January 13, 2025, CESC share price opened at ₹161.00, down from its previous close of ₹162.42. At 11:27 AM, the share price of CESC was trading at ₹157.07, down by 3.29% on the NSE. As of the same time, the stock touched its day’s low at ₹152.77.

Q3 FY 2025 Financial Highlights 

On January 10, 2025, the company provided an update for the third quarter of FY 2025. For Q3 FY25, the company reported gross revenue of ₹3,657 crore, reflecting a growth of 10.8% compared to ₹3,301 crore in Q3 FY24. The EBITDA for the quarter stood at ₹1,006 crore, an increase of 4.5% over ₹963 crore in the same quarter last year. However, the PAT (Profit After Tax) decreased by 6.3%, coming in at ₹282 crore, down from ₹301 crore in Q3 FY24.

For the nine-month period of FY25, the company reported a gross revenue of ₹13,345 crore, marking a 10.4% increase from ₹12,084 crore in the same period last year. The EBITDA for 9MFY25 stood at ₹3,206 crore, up by 4.1% from ₹3,079 crores in 9MFY24. PAT for the nine months was ₹1,043 crore, an increase of 1.1% compared to ₹1,032 crore in the previous year.

Interim Dividend Declaration and Record Date

The company has declared an interim dividend of ₹4.50 per equity share (i.e., 450%) on its paid-up equity share capital. This dividend will be payable to members whose names are listed in the Register of Members or those who appear as beneficial owners, as per the details provided by the Depositories, namely National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL), as of the close of business on January 16, 2025, the Record Date to determine eligibility for the interim dividend.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

IndusInd Bank Limited is in focus on Monday. On January 13, 2025, IndusInd Bank share price opened at ₹936.90, down from its previous close of ₹937.60. However, at 11:04 AM, the share price of IndusInd Bank was trading at ₹962.50, up by 2.66% on the NSE. As of the same time, the stock touched its day’s high at ₹973.50.

In December 2024, IndusInd Bank celebrated its 30th anniversary, marking three decades of leading technological advancements and digital innovations that have shaped the future of banking in India. To commemorate this milestone, the Bank announced its partnership with India Post to launch Customised My Stamps.

Financial Highlights for the Quarter ended September 30, 2024

For the quarter ended September 30, 2024, Net Interest Income stood at ₹5,347 crore, marking a 5% YoY growth. The Net Interest Margin (NIM) for Q2 FY 2025 was 4.08%, compared to 4.29% in Q2 FY 2024 and 4.25% in Q1 FY 2025. The decrease in NIM was primarily due to a reduction in the share of microfinance loans in the overall loan portfolio.

The Yield on Assets remained consistent at 9.69% for both the quarter ended September 30, 2024, and the same period in the previous year. The Cost of Funds increased to 5.61%, from 5.40% in the corresponding quarter of the previous year.

Other income for the quarter was ₹2,185 crores, compared to ₹2,282 crores in the same quarter last year. Core Fee income was ₹2,125 crores, slightly higher than ₹2,120 crores reported in the corresponding quarter of the previous year.

Operating expenses for the quarter were ₹3,932 crores, up from ₹3,450 crores in the same quarter of the previous year.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

HCL Technologies Limited (HCLTech) is gaining attention on Monday ahead of the Q3 FY 2025 financial results announcement. On January 13, 2025, HCL share price (NSE: HCLTECH) opened at ₹1,994.90, slightly down from its previous close of ₹1,995.10. At 10:10 AM, the share price of HCLTech was trading at ₹1,985.30, down by 0.49% on the NSE. Notably, the stock touched its 52-week high at ₹2,002.35 recently on January 10, 2025.

Board Meeting Announcement and Interim Dividend Declaration

In December 2024, the company announced that its Board of Directors would convene on Monday, January 13, 2025, to discuss key financial matters. The meeting’s agenda includes the review of the unaudited financial results for the quarter and the nine months ending December 31, 2024, along with the consideration of the 4th Interim Dividend for the financial year 2024-25.

Financial Performance in Q2 FY 2025

For Q2 FY 2025, the company’s revenue reached ₹28,862 crore, reflecting a growth of 2.9% quarter-on-quarter (QoQ) and 8.2% year-on-year (YoY). The Earnings Before Interest and Tax (EBIT) stood at ₹5,362 crore, which constitutes 18.6% of the total revenue, showing a 11.8% increase QoQ and an 8.7% rise YoY.

During the second quarter, the Board declared an Interim Dividend of ₹12 per equity share for the financial year 2024-25. The Record Date for this dividend was set for October 22, 2024, with the payment date scheduled for October 30, 2024.

 

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.